About this document "ALK/ROS1/RET fusions (NGS)": who should get this test

Based on the document content, I can provide specific guidance on who should receive ALK/ROS1/RET fusion testing:

According to the document and supported by authoritative sources:

1. Primary Patient Population:

• Patients with metastatic non-squamous NSCLC (Non-Small Cell Lung Cancer)
• Patients in the "Newly Diagnosed" care phase

This aligns with multiple authoritative guidelines:

According to the NCCN 2024 Guidelines (as referenced in the document):

• Molecular testing for ALK, ROS1, and RET fusions is considered standard of care for patients with non-squamous NSCLC at diagnosis of metastatic disease

The American Society of Clinical Oncology (ASCO) guidelines support this by recommending:

• Testing for ALK, ROS1, and RET fusions should be conducted at diagnosis for all patients with advanced non-squamous NSCLC

National Cancer Institute (NCI) guidance also indicates:

• These biomarker tests are essential for identifying patients who may benefit from targeted therapies (TKIs - Tyrosine Kinase Inhibitors, as mentioned in the document's purpose)

Important Note: While these are the general guidelines, patients should always consult with their healthcare providers to determine if this testing is appropriate for their specific situation, as individual cases may vary.